Appl. No. 10/826,797 Amend. dated June 14, 2005

Response to Office Action mailed on: March 22, 2005

Amendments to the Claims:

- 1. (Currently amended) A method of treatment of allergie asthma-treating late asthmatic response in a patient comprising administering to the patient a maintenance dose of an IgE antagonist and, optionally, a loading dose of the IgE antagonist wherein said IgE antagonist is (a) an antibody or antigen-binding fragment thereof, that prevents the binding of free IgE to FceRI, but does not bind to FceRI-bound IgE, (b) a soluble IgE receptor or (c) or an IgE binding peptide capable of disrupting or blocking the interaction between IgE and its receptors.
- 2. (Original) The method of claim 1, wherein the maintenance dose is repeated at intervals of about 1 to about 90 days.
- 3. (Original) The method of claim 2, wherein the maintenance dose is repeated weekly.
- 4. (Original) The method of claim 2, wherein the maintenance dose is repeated biweekly.
- 5. (Original) The method of claim 1, wherein the IgE antagonist is an anti-IgE antibody.
- 6. (Original) The method of claim 5, wherein the antibody is chimeric.
- 7. (Original) The method of claim 6, wherein the antibody is humanized.
- 8. (Original) The method of claim 5, wherein the antibody is a human antibody.
- 9. (Original) The method of claim 1, wherein the antagonist binds to soluble IgE and blocks the binding of IgE to the IgE receptor on basophils.
- 10. (Original) The method of claim 5, wherein the antibody binds to soluble IgE and blocks the binding of IgE to the IgE receptor on basophils.
- 11. (Original) The method of claim 1, wherein the loading dose is administered before onset of asthma symptoms.
- 12. (Original) The method of claim 1, wherein the loading dose is administered after the onset of asthma symptoms.
- 13. (Original) The method of claim 1, wherein the loading dose is greater than the maintenance dose.

Appl. No. 10/826,797 Amend. dated June 14, 2005 Response to Office Action mailed on: March 22, 2005

- 14. (Original) The method of claim 1, wherein the antagonist is administered in a formulation comprising a buffer, a salt, optionally, a polyol, and optionally, a preservative.
- 15. (Original) The method of claim 14, wherein the antagonist is freeze-dried, then reconstituted before administration.
- 16. (Original) The method of claim 1, wherein the maintenance dose, and optionally, the loading dose reduce the concentration of free IgE in the patient's serum to less than about 40 ng/ml.
- 17. (Original) The method of claim 1, wherein the maintenance dose of antagonist is about 0.001 to 0.01 mg/kg/week/baseline IgE IU/ml.
- 18. (Original) The method of claim 1, wherein the maintenance dose, and optionally, the loading dose, results in a total serum concentration of antagonist of about 1 to 10 times greater than the patient's total serum IgE concentration.
- 19. (Currently amended) A method for treating allergic asthmalate asthmatic response in a patient comprising administering to the patient a dose of IgE antagonist averaging about 0.001 to 0.01 mg/kg/week IgE antagonist for every IU/ml baseline IgE in the patient's serum, wherein said IgE antagonist is (a) an antibody or antigen-binding fragment thereof, that prevents the binding of free IgE to FceRI, but does not bind to FceRI-bound IgE, (b) a soluble IgE receptor or (c) or an IgE binding peptide capable of disrupting or blocking the interaction between IgE and its receptors.

20-39. Canceled

- 40 (New). A method of treating allergic asthma comprising a maintenance dose of an anti-IgE antibody in combination with the administration of an adjuvant selected from the group consisting of antihistamine, theophylline, salbutamol, beclomethasone, diproprionate, sodium cromoglycate, a steroid and an anti-inflammatory agent.
- 41 (New). The method of Claim 40, wherein the adjuvant is administered before the anti-IgE antibody.
- 42 (New). The method of Claim 40, wherein the adjuvant is administered after the IgE antibody.
- 43 (New). The method of Claim 40, wherein the adjuvant is antihistamine.

Appl. No. 10/826,797

Amend. dated June 14, 2005

Response to Office Action mailed on: March 22, 2005

- 44 (New). The method of Claim 40, wherein the adjuvant is theophylline.
- 45 (New). The method of Claim 40, wherein the adjuvant is salbutamol.
- 46 (New). The method of Claim 40, wherein the adjuvant is beclomethasone.
- 47 (New). The method of Claim 40, wherein the adjuvant is diproprionate.
- 48 (New). The method of Claim 40, wherein the adjuvant is sodium cromoglycate.
- 49 (New). The method of Claim 40, wherein the adjuvant is a steroid.
- 50 (New). The method of Claim 40, wherein the adjuvant is an anti-inflammatory agent.